**Results** Patients with SLE had higher cfDNA (1.69±0.23 vs 1.42±031 ng/mL, p=0.0003), MPO (1607±2353 vs 1503 ±1106, p<0.05) and BAFF levels (160735±2353.23 vs 891.16±184.31, p<0.05). DNAse concentration was also lower in healthy controls (5.84±5.72 vs 9.38±6.97, p<0.05). BAFF showed strong correlation with anti-dsDNA antibodies determined by ELISA method ($\rho$=0.564, p=0.000), MPO activity ($\rho$=0.256, p=0.021), DNAse I concentration ($\rho$=0.27, p=0.012) and cfDNA concentration ($\rho$=0.262, p=0.014). DNA determined by ELISA test showed correlations with DNAse concentration ($\rho$=0.249, p=0.022), DNA determined by CLIFT ($\rho$=0.341, p=0.001) and C3 complement component ($\rho$=−0.4, p=0.023). MPO activity showed correlations with cfDNA levels ($\rho$=0.386, p=0.001), DNAse concentration ($\rho$=0.501, p=0.000), and anti-MPO antibodies ($\rho$=0.293, p=0.006). Cell free DNA levels additionally correlated with DNAse activity ($\rho$=0.288, p=0.007) as well with netolytic activity ($\rho$=0.244, p=0.026). Netolytic activity also correlated with anti-dsDNK antibodies determined by ELISA ($\rho$=−0.299, p=0.039).

**Conclusions** Increased NETs` footprints (myeloperoxidase and cfDNA) are present in lupus sera. As probably compensatory mechanism increased DNAse I concentrations also were found in lupus sera. NET burden is followed by production of various antibodies recognising different NET structures.

# S3d – APS

E Kiss, A Szappanos, A Wiedemann, A Balogh, M Szabo, G Poor. *National Institution of Rheumatology and Physiotherapy, Budapest, Hungary*

Recurrent thrombotic events occur in 20% of patients with APS despite of adequate antithrombotic therapy. As phospholipid-cofactor antibodies are key elements of pathophysiology, B cell depleting rituximab is a rational therapeutic approach.

Aims were to identify and characterise APS patients receiving rituximab. All together 179 (60 primary, 119 lupus-associated) APS patients were found in our database of whom 15 (8.4%) were treated with RTX. As younger and male patients dominated in RTX +group, 15 from RTX naive patients were matched regarding age and gender for a case control study. First symptoms appeared at the age of 30 in both groups. Patients were followed for 4 and 7 years, the diagnosis delayed 4 and 1 year in RTX +and RTX- groups, respectively. This 3 year difference might contribute to higher disease severity. Primary APS (47% vs 32%), cerebrovascular events (13 vs 2), valvular heart disease (5 vs 2), and high risk triple aPL positivity (13 vs 5) were more prevalent in RTX +group. All 4 deep venous thrombosis cases in the RTX +group were complicated with pulmonary embolism in comparison with 1 PE within 6 RTX- DVT patients. Raynaud syndrome resulted in digital ulcer more frequently in RTX +than in RTX- group (4/4 vs 1/6). Antimalarials were given to 3 and 10, cumarin or NOAC were iniciated in 15 and 5 patients in the RTX +and RTX- groups, respectively. Rituximab was started 2

(0.5–6) years after diagnosis. Within 10 (3–60) moths follow-up on RTX there were no incident thrombotic events. Two thirds of patients could stop steroid. RTX was stopped in 6 cases: 3 due to remission (of whom 2 relapsed), 1 LFU, and 2 adverse events (1 longstanding B cell depletion, 1 peroneus paresis). Other AEs were 1 mild infusion reaction, 1 leukopenia, 1 UTI. As summarised, delay in APS diagnosis and male gender were associated with more severe disease and the need for rituximab. Antimalarials and associating lupus were identified as markers of more favourable disease outcome. In patients with recurrent thrombotic events despite of adequate anticoagulant therapy, RTX can be a rational and effective choice with favourable safety profile.

[1]Y Molad, [1,2]Y Edel, [1,2]E Pokroy-Shapira, [1,2]S Oren, [1,2]A Dortort, [1]Y Pri-Paz Basson, [2,3]T Shochat, [2,4]V Kliminski. *[1]Rheumatology Unit, Beilinson Hospital-Rabin Medical Centre, Petach Tikva, Israel; [2]Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; [3]Bio-Statistical Unit, Beilinson Hospital, Rabin Medical Centre, Petach Tikva, Israel; [4]Laboratory of Inflammation Research, Felsenstein Medical Research Centre, Rabin Medical Centre, Petach Tikva, Israel*

**Background** Antiphospholipid antibodies (APLA) are necessary, but not sufficient for the development of thrombosis in APS. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an innate-immune receptor found in the blood and reflects innate immune cells activation.

**Aim** To determine if plasma sTREM-1 can be served as a biomarker for thrombosis in patients with PAPS.

**Methods** A cross-sectional, case-control study. Plasma level of sTREM-1 was analysed by ELISA in a group of consecutive patients diagnosed with either PAPS (Sapporo criteria) or asymptomatic persistently positive APLA, and healthy controls (HC).

**Results** The study group comprised of 33 patients with PAPS (age 52.0±17.4 years.), 10 asymptomatic APLA-positive patients (50.6±17.9 years.) and 73 HC (42.6±13.3 years.). The mean plasma sTREM-1 level was significantly higher in the PAPS group compared to HC (316.3±119.3 pg/ml, vs 230.2±85.5 pg/ml, p=0.0002), as well as past obstetric APS (195.12±58.52 pg/ml, p=0.014), and asymptomatic APLA (215.8±pg/ml vs HC, p=0.019). Plasma sTREM-1 in PAPS patients with an acute event of thrombosis was significantly higher than in patients with past thrombotic event (p=0.012), past obstetric APS (p=0.0001) and HC (p<0.0001). Plasma sTREM-1 level was significantly higher in PAPS patients who ever had stroke (p=0.007) or venous thromboembolic event (p=0.018). On receiver operator curve (ROC) analysis, plasma sTREM-1 showed an area under the curve (AUC) 0.7292 in differentiating between thrombotic APS (ever) and non-thrombotic APS or asymptomatic APLA-positivity. A multivariate regression model to predict sTREM-1 level by thrombotic PAPS ever, age and sex found that sTREM-1 level is independently associated with thrombotic PAPS (p<0.004) as well as with female gender (p=0.017) and older age (p=0.0006). Plasma sTREM-1 level was neither associated with anti-cardiolipin, anti-β2 glycoprotein I (IgG/IgM/IgA) Abs' titers and/or